In Alzheimer disease brains, NMNAT2 levels are less than 50% of control levels, and we propose that enhancing NMNAT2 function may provide an effective therapeutic intervention to reserve cognitive function. The gene discussed is NMNAT2; the disease is early-onset autosomal dominant Alzheimer disease.